Fosun Pharma's FXR0906 Injection Enters Phase II Clinical Trial in China for Hypertriglyceridemia Treatment
Stock News
Yesterday
Fosun Pharma (02196) announced that its controlling subsidiary, Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd., has recently launched a Phase II clinical trial in China for FXR0906 injection for the treatment of hypertriglyceridemia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.